SEARCH

SEARCH BY CITATION

References

  • 1
    Van Diest PJ, Van Der Wall E, Baak JP. Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol 2004; 57: 67581.
  • 2
    Sherr CJ. Cancer cell cycles. Science 1996; 274: 16727.
  • 3
    Pines J. Cyclins and cyclin-dependent kinases: a biochemical view. Biochem J 1995; 308: 697711.
  • 4
    Smits VA, Medema RH. Checking out the G(2)/M transition. Biochim Biophys Acta 2001; 1519: 112.
  • 5
    Wang A, Yoshimi N, Ino N, Tanaka T, Mori H. Overexpression of cyclin B1 in human colorectal cancers. J Cancer Res Clin Oncol 1997; 123: 1247.
  • 6
    Kallakury BV, Sheehan CE, Rhee SJ et al. The prognostic significance of proliferation-associated nucleolar protein p120 expression in prostate adenocarcinoma: a comparison with cyclins A and B1, Ki-67, proliferating cell nuclear antigen, and p34cdc2. Cancer 1999; 85: 156976.
  • 7
    Allan K, Jordan RC, Ang LC, Taylor M, Young B. Overexpression of cyclin A and cyclin B1 proteins in astrocytomas. Arch Pathol Lab Med 2000; 124: 21620.
  • 8
    Rudolph P, Kuhling H, Alm P et al. Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node-negative breast cancer. Int J Cancer 2003; 105: 67480.
  • 9
    Pines J, Hunter T. Human cyclins A and B1 are differentially located in the cell and undergo cell cycle-dependent nuclear transport. J Cell Biol 1991; 115: 117.
  • 10
    Nozoe T, Korenaga D, Kabashima A, Ohga T, Saeki H, Sugimachi K. Significance of cyclin B1 expression as an independent prognostic indicator of patients with squamous cell carcinoma of the esophagus. Clin Cancer Res 2002; 8: 81722.
  • 11
    Winters ZE, Hunt NC, Bradburn MJ et al. Subcellular localisation of cyclin B, Cdc2 and p21 (WAF1/CIP1) in breast cancer. association with prognosis. Eur J Cancer 2001; 37: 240512.
  • 12
    Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer. Experience from a large study with long-term follow-up. Histopathology 1991; 19: 40310.
  • 13
    Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ, Panel members. Meeting highlights: international expert consensus on the primary therapy of early breast cancer. Ann Oncol 2005; 10: 156983.
  • 14
    Innocente SA, Abrahamson JL, Cogswell JP, Lee JM. p53 regulates a G2 checkpoint through cyclin B1. Proc Natl Acad Sci USA 1999; 96: 214752.
  • 15
    Taylor WR, DePrimo SE, Agarwal A et al. Mechanisms of G2 arrest in response to overexpression of p53. Mol Biol Cell 1999; 10: 360722.
  • 16
    Sheen JH, Woo JK, Dickson RB. c-Myc alters the DNA damage-induced G2/M arrest in human mammary epithelial cells. Br J Cancer 2003; 89: 147985.
  • 17
    Toyoshima-Morimoto F, Taniguchi E, Shinya N, Iwamatsu A, Nishida E. Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase. Nature 2001; 410: 21520.
  • 18
    Yuan J, Eckerdt F, Bereiter-Hahn J, Kurunci-Csacsko E, Kaufmann M, Strebhardt K. Cooperative phosphorylation including the activity of polo-like kinase 1 regulates the subcellular localization of cyclin B1. Oncogene 2002; 21: 828292.
  • 19
    Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B. 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 1999; 401: 61620.
  • 20
    Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983; 31: 1320.
  • 21
    Dutta A, Chandra R, Leiter LM, Lester S. Cyclins as markers of tumor proliferation: immunocytochemical studies in breast cancer. Proc Natl Acad Sci USA 1995; 92: 538690.
  • 22
    Kuhling H, Alm P, Olsson H et al. Expression of cyclins E, A, and B, and prognosis in lymph node-negative breast cancer. J Pathol 2003; 199: 42431.
  • 23
    Innocente SA, Lee JM. p53 is a NF-Y- and p21-independent, Sp1-dependent repressor of cyclin B1 transcription. FEBS Lett 2005; 579: 10017.
  • 24
    Yin XY, Grove L, Datta NS, Katula K, Long MW, Prochownik EV. Inverse regulation of cyclin B1 by c-Myc and p53 and induction of tetraploidy by cyclin B1 overexpression. Cancer Res 2001; 61: 648793.
  • 25
    Hurlimann J, Chaubert P, Benhattar J. p53 gene alterations and p53 protein accumulation in infiltrating ductal breast carcinomas: correlation between immunohistochemical and molecular biology techniques. Mod Pathol 1994; 7: 4238.
  • 26
    Wolf G, Hildenbrand R, Schwar C et al. Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer. Pathol Res Pract 2000; 196: 7539.
  • 27
    Weichert W, Kristiansen G, Winzer KJ et al. Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications. Virchows Arch 2005; 446: 44250.
  • 28
    Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene 2001; 20: 180315.
  • 29
    Dowlatshahi K, Fan M, Snider HC, Habib FA. Lymph node micrometastases from breast carcinoma: reviewing the dilemma. Cancer 1997; 80: 118897.
  • 30
    Colman MS, Afshari CA, Barrett JC. Regulation of p53 stability and activity in response to genotoxic stress. Mutat Res 2000; 462: 17988.
  • 31
    Tarapore P, Fukasawa K. p53 mutation and mitotic infidelity. Cancer Invest 2000; 18: 14855.
  • 32
    Kao GD, McKenna WG, Maity A, Blank K, Muschel RJ. Cyclin B1 availability is a rate-limiting component of the radiation-induced G2 delay in HeLa cells. Cancer Res 1997; 57: 7538.
  • 33
    Park M, Chae HD, Yun J et al. Constitutive activation of cyclin B1-associated cdc2 kinase overrides p53-mediated G2–M arrest. Cancer Res 2000; 60: 5425.
  • 34
    Yuan J, Yan R, Kramer A et al. Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells. Oncogene 2004; 23: 584352.
  • 35
    Hassan KA, Ang KK, El-Naggar AK et al. Cyclin B1 overexpression and resistance to radiotherapy in head and neck squamous cell carcinoma. Cancer Res 2002; 62: 641417.
  • 36
    Kaufmann WK, Levedakou EN, Grady HL, Paules RS, Stein GH. Attenuation of G2 checkpoint function precedes human cell immortalization. Cancer Res 1995; 55: 711.
  • 37
    Chang TH, Schlegel R. SV40 T antigen increases the expression and activities of p34cdc2, cyclin A, and cyclin B prior to immortalization of human diploid fibroblasts. J Cell Biochem 1996; 60: 16172.